Rigel Pharmaceuticals, MD Anderson partner to evaluate REZLIDHIA in AML

Rigel Pharmaceuticals and The University of Texas MD Anderson Cancer Center announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA in acute myeloid leukemia and other hematologic cancers. The alliance brings together MD Anderson’s clinical research expertise with Rigel’s differentiated targeted molecule. Under the strategic collaboration, Rigel and MD Anderson will evaluate the potential of olutasidenib to treat newly diagnosed and relapsed or refractory patients with AML, higher-risk myelodysplastic syndromes, and advanced myeloproliferative neoplasms, in combination with other agents. The collaboration will also support the evaluation of olutasidenib as monotherapy in lower-risk MDS and as maintenance therapy in post-hematopoietic stem cell transplant patients.